Cover Image
市場調查報告書

美國的癌症疫苗市場:明亮的未來展望

Promising Outlook - US Cancer Vaccine Market

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 622430
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
美國的癌症疫苗市場:明亮的未來展望 Promising Outlook - US Cancer Vaccine Market
出版日期: 2018年08月14日 內容資訊: 英文 135 Pages
簡介

本報告提供美國國內的癌症疫苗市場現況與未來展望相關分析,疾病、產品概要,及主要推動及阻礙市場要素,目前主要癌症疫苗其未來性,各產品種類、各用途的市場趨勢預測,開發中產品臨床實驗趨勢,主要的相關專利的認證的動向,主要企業簡介等調查。

第1章 分析師的見解

第2章 分析方法

第3章 癌症患者數的統計資料

  • 癌症患病人數、發病數量、死亡人數
  • 在主要國家的發病數量
  • 主要的癌症的發病數量
    • 男性的癌症發病數量
    • 女性的癌症發病數量
    • 兒童的癌症發病數量

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第5章 癌症疫苗市場未來展望

  • 主要產品分析
    • Provenge
    • T-Vec/Imlygic
    • 人類乳突病毒 (HPV) 疫苗
    • B型肝炎 (HBV) 疫苗

第6章 癌症疫苗市場:癌症的各類型

第7章 癌症疫苗市場:各用途

第8章 癌症疫苗的未來候補:市場機會的評估

  • 預防疫苗
  • 治療疫苗
    • 前列腺癌症
    • 乳癌
    • 肺癌症
    • 直腸結腸癌症

第9章 美國專利分析

  • 專利認證趨勢:各年度
  • 專利認證趨勢:各類別
    • 一般專利
    • 設計專利
    • 植物專利
  • 專利認證趨勢:各企業
  • 專利認證趨勢:申請人的各類型
    • 申請人的名稱
    • 申請人的所屬州

第10章 法規環境

  • 疫苗的認證流程
  • FDA (聯邦食品藥物管理局)的產業的指南:癌症治療疫苗臨床實驗的考慮事項
    • 以臨床實驗的早期、後期階段的雙方應考慮的事項
    • 臨床實驗的早期階段應考慮的事項
    • 臨床實驗的後期階段應考慮的事項

第11章 競爭環境

第12章 企業簡介

  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Dendreon Pharmaceuticals LLC
  • Amgen Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Cancer involves abnormal and uncontrolled cell growth which may spread to other parts of the body as well. According to GLOBOCAN, in 2015, approximately 15.2 Million incidences of cancer were registered all across the globe. Out of total, US accounted for approximately 1.7 Million incidences of this deadly disease. Cancer is also one of the leading causes of mortality. Traditional treatment options, such as surgery, chemotherapy and radiotherapy, have several drawbacks such as hair loss, abnormal blood cell count and nausea. One of the major drawbacks of traditional cancer treatment therapies is the risk of remission in patient.

Owing to all these shortcomings, researchers are developing novel treatment options, such as cancer vaccines, for this disease. Cancer vaccines have always been considered as high potential method for preventing and treating cancer even though they have not been able to achieve their expected sales. However, the market for these vaccines is expected to witness decent growth in the coming years due to the launch of new cancer vaccines and increasing awareness among people about this treatment option.

According to the RNCOS report entitled "Promising Outlook - US Cancer Vaccine Market", the US is largest market for cancer vaccines amongst all the geographic regions worldwide. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing cancer incidences in the country, rising awareness, and strong pipeline, for the US Cancer Vaccines Market. Furthermore, the report also gives information related to the commercially available cancer vaccines. It also covers the restraints hampering the growth of the market, and future opportunities.

On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounted for the largest share in 2017. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline.

Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.

The prominent players in US Cancer Vaccines Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the US Cancer Vaccines Market.

1. Analyst View

2. Research Methodology

3. Cancer Statistics by Demographics

  • 3.1 Prevalence, Incidences and Mortality
  • 3.2 Leading States by Incidences
  • 3.3 Leading Cancers by Incidences
    • 3.3.1 Male Cancer Incidences
    • 3.3.2 Female Cancer Incidences
    • 3.3.3 Children Cancer Incidences

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Rising Cancer Incidences
    • 4.1.2 Ability to Reduce Healthcare Expenditure
    • 4.1.3 Rising Awareness
    • 4.1.4 Patient Assistance Programs
    • 4.1.5 Government Initiatives
    • 4.1.6 Strong Pipeline
    • 4.1.7 Technological Advancements
  • 4.2 Restraints
    • 4.2.1 High Cost of Cancer Vaccines
    • 4.2.2 Side-Effects of Cancer Vaccines
    • 4.2.3 Vaccine Supply Shortages
    • 4.2.4 Insurance Issues Related to Cancer Vaccination
  • 4.3 Opportunities
    • 4.3.1 Therapeutic Cancer Vaccines
    • 4.3.2 Adjuvant Cancer Vaccines

5. Cancer Vaccines Market Outlook

  • 5.1 Key Product Analysis
    • 5.1.1 Provenge
      • 5.1.1.1 Market Analysis
    • 5.1.2 T-Vec/Imlygic
      • 5.1.2.1 Market Analysis
    • 5.1.3 HPV Vaccine
      • 5.1.3.1 Gardasil
      • 5.1.3.1.1 Market Analysis
      • 5.1.3.2 Cervarix
      • 5.1.3.2.1 Market Analysis
    • 5.1.4 HBV Vaccines
      • 5.1.4.1 Engerix-B & Twinrix
      • 5.1.4.1.1 Market Analysis
      • 5.1.4.2 Recombivax HB
      • 5.1.4.2.1 Market Analysis
      • 5.1.4.3 Pediarix/ Infanrix
      • 5.1.4.3.1 Market Analysis

6. Cancer Vaccines Market by Cancer Type

7. Cancer Vaccine Market by Application

8. Potential Cancer Vaccine Candidates: An Opportunity Assessment

  • 8.1 Prophylactic Vaccine
  • 8.2 Therapeutic Vaccine
    • 8.2.1 Prostate Cancer
    • 8.2.2 Breast Cancer
    • 8.2.3 Lung Cancer
    • 8.2.4 Colorectal Cancer

9. US Patent Analysis

  • 9.1 Patents by Year
  • 9.2 Patents by Category
    • 9.2.1 Utility Patents
    • 9.2.2 Design Patents
    • 9.2.3 Plant Patents
  • 9.3 Patents by Company
  • 9.4 Patents by Assignee Type
    • 9.4.1 By Assignee Name
    • 9.4.2 By Assignee State

10. Regulatory Environment

  • 10.1 Vaccine Approval Process
  • 10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
    • 10.2.1 Considerations for both Early and Late Phase Clinical Trials
      • 10.2.1.1 Patient Population
      • 10.2.1.2 Monitoring the Immune Response
      • 10.2.1.3 Biomarkers as Evidence of Efficacy
      • 10.2.1.4 Adjuvants Used to Stimulate Immune Response
      • 10.2.1.5 Multi-antigen Vaccines
      • 10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines
      • 10.2.1.7 Concomitant and Subsequent Therapies
    • 10.2.2 Considerations for Early Phase Clinical Trials
      • 10.2.2.1 Starting Dose and Dosing Schedule
      • 10.2.2.2 Booster and Maintenance Therapy
      • 10.2.2.3 Dose Escalation
      • 10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development
    • 10.2.3 Considerations for Late Phase Clinical Trials
      • 10.2.3.1 Safety Profile from Early Phase Clinical Trials
      • 10.2.3.2 Endpoints
      • 10.2.3.3 Statistical Issues
      • 10.2.3.4 Control Issues
      • 10.2.3.5 Delayed Vaccine Effect
      • 10.2.3.6 Autologous Vaccine Trials
      • 10.2.3.7 Accelerated Approval Regulations

11. Competitive Landscape

12. Company Profiles

  • 12.1 Merck & Co., Inc.
  • 12.2 GlaxoSmithKline plc.
  • 12.3 Dendreon Pharmaceuticals LLC
  • 12.4 Amgen Inc.

List of Figures:

  • Figure 3-1: Cancer Incidences (Million), 2015 & 2025
  • Figure 3-2: Cancer Mortality (Million), 2015 & 2025
  • Figure 3-3: Incidences by Cancer Type (%), 2018
  • Figure 3-4: States with Highest Cancer Incidences, 2018
  • Figure 5-1: Global - Cancer Vaccine Market (Million US$), 2016-2023
  • Figure 5-2: US - Cancer Vaccine Market (Million US$), 2016-2023
  • Figure 5-3: Share of US in Global Cancer Vaccine Market (%), 2017
  • Figure 5-4: US - Cancer Vaccine Market by Product Type (%), 2017
  • Figure 5-5: US - Provenge Market (Million US$), 2013-2017
  • Figure 5-6: Share of US in Global Imlygic Sales (%), 2017
  • Figure 5-7: Global - Gardasil Market (Million US$), 2013-2017
  • Figure 5-8: US - Gardasil Market (Million US$), 2013-2017
  • Figure 5-9: Share of US in Global Gardasil Sales (%), 2017
  • Figure 5-10: Global - Cervarix Market (Million US$), 2013-2017
  • Figure 5-11: US - Cervarix Market (Million US$), 2013-2017
  • Figure 5-12: Share of US in Global Cervarix Sales (%), 2017
  • Figure 5-13: Global - Engerix-B & Twinrix Market (Million US$), 2013-2017
  • Figure 5-14: US - Engerix-B & Twinrix Market (Million US$), 2013-2017
  • Figure 5-15: Share of US in Global Engerix-B & Twinrix Sales (%), 2017
  • Figure 5-16: Global - Recombivax HB Market (Million US$), 2013-2017
  • Figure 5-17: US - Recombivax HB Market (Million US$), 2013-2017
  • Figure 5-18: Share of US in Global Recombivax HB Sales (%), 2017
  • Figure 5-19: Global - Pediarix/Infanrix Market (Million US$), 2013-2017
  • Figure 5-20: US - Pediarix/ Infanrix Market (Million US$), 2013-2017
  • Figure 5-21: Share of US in Global Pediarix/Infanrix Sales (%), 2017
  • Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2017
  • Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2016-2023
  • Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2016-2023
  • Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2016-2023
  • Figure 7-1: US - Cancer Vaccine Market by Application (%), 2017
  • Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2016-2023
  • Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2016-2023
  • Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017
  • Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2017
  • Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017
  • Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2017
  • Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2017
  • Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2017
  • Figure 12-1: Merck & Co., Inc. - Breakup of Sales by Business Segment (%), 2017
  • Figure 12-2: Merck & Co., Inc. - Breakup of Sales by Geography (%), 2017
  • Figure 12-3: GlaxoSmithKline - Breakup of Group Turnover by Business Segment (%), 2017
  • Figure 12-4: GlaxoSmithKline - Breakup of Group Turnover by Geography (%), 2017
  • Figure 12-5: Amgen Inc. - Breakup of Revenue by Geography (%), 2017

List of Tables:

  • Table 3-1: Top 10 Cancer Incidences in Males (2018)
  • Table 3-2: Top 10 Cancer Incidences in Females (2018)
  • Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2018)
  • Table 4-1: Cancer Incidences (Million), 2015, 2020 & 2025
  • Table 8-1: Cancers with High Linkage to Virus and Bacteria
  • Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
  • Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
  • Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
  • Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
  • Table 12-1: Merck & Co., Inc. - Key Financials (Million US$), 2015-2017
  • Table 12-2: Merck & Co., Inc. - Product Portfolio
  • Table 12-3: Merck & Co., Inc. - Cancer Vaccines in Pipeline
  • Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2015-2017
  • Table 12-5: GlaxoSmithKline - Product Portfolio
  • Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
  • Table 12-7: Dendreon Pharmaceuticals LLC - Product Portfolio
  • Table 12-8: Amgen Inc. - Key Financials (Million US$), 2015-2017
  • Table 12-9: Amgen Inc. - Product Portfolio
Back to Top